A sequence-randomized, open-label, single dose, crossover study to evaluate pharmacokinetics and safety after oral administration of Plavix (75mg) and Astrix (100mg) in free combination and fixed-dose combination as HCP0911 in healthy male volunteers.

Trial Profile

A sequence-randomized, open-label, single dose, crossover study to evaluate pharmacokinetics and safety after oral administration of Plavix (75mg) and Astrix (100mg) in free combination and fixed-dose combination as HCP0911 in healthy male volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs Aspirin/clopidogrel (Primary) ; Aspirin; Clopidogrel
  • Indications Cardiovascular disorders; Thrombosis
  • Focus Pharmacokinetics
  • Acronyms HM-CPAS-101
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 25 Aug 2016 Last checked against Korean Clinical Trials Register
    • 09 Mar 2013 Results presented at the 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 23 Nov 2011 Official Title amended as reported by Clinical Research Information Service (CriS) - Republic of Korea record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top